# Samsung Biologics signs $325M manufacturing pact with Celltrion

Samsung Biologics finalized a $325 million multi-year manufacturing agreement with Celltrion to produce key biologics. The contract leverages Samsung Biologics' CDMO capabilities to support Celltrion's biosimilar portfolio.

- Type: Contract
- Announced: 2026-11-07
- Where: South Korea
- Value: $325.0M
- Status: completed
- Products: biologics, biosimilars
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Samsung Biologics](https://endata.com/companies/15584.md) (supplier)
- [Celltrion](https://endata.com/companies/15585.md) (customer)

## Sources

- [inforcapital.com](https://inforcapital.com/news/samsung-biologics-lands-325-mn-celltrion-order-in-first-major-production-tie-up/), 2026-11-07: "Samsung Biologics secures a significant $325 million manufacturing contract with Celltrion, bolstering biosimilar production and global supply chains."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.